Pharmacological treatment of menopause in Spain in 2002;Tratamiento farmacológico de la menopausia en España en 2002

Clinica e Investigacion en Ginecologia y Obstetricia

Volumn 30, Issue 9, 2003, Pages 299-306

  Calaf, J ^a   Ferrer, M ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GESTAGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CALCULATION; CLIMACTERIUM; CLINICAL PRACTICE; DATA ANALYSIS; DATA BASE; DRUG INDICATION; DRUG MARKETING; DRUG USE; ECONOMIC ASPECT; ESTROGEN THERAPY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCOME; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; POSTMENOPAUSE; PRESCRIPTION; SPAIN;

EID: 0346655297     PISSN: 0210573X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-573X(03)77277-3     Document Type: Article

References (19)

1. Black DM, Cummings SR, Karf DB, Cauley JA, Thompson DE, Newitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82.
3. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000;85:4118-24.
4. Harris ST, Watts NB, Genant HK, McKeever CD, Haugartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.
5. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandy ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
6. McClung MR, Geusens P, Miller PD, Zippel M, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
7. Ettinger B, Black D, Cummings S, Genant H, Gluer C, Lipp P, et al. Raloxifene reduces the risk of incident vertebral fractures: 24 months interim analysis. Osteoporosis Int 1998;8(Suppl 3):11.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
9. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2003;360:942-4.
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Rlggs B, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
11. Instituto Nacional de Estadística. Poblaciones de derecho por grupos de edad y sexo. Proyecciones a partir del censo de población de 1991. Boletín Mensual de Estadística (BME) 2001;120:35.
12. Thorp JM, Gavin NI, Ohsfeldt RL. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users. Am J Obstet Gynecol 2001;185:318-26.
13. Groeneveld FPMJ, Bareman FP, Barentsen R, Dokten HJ, Drogendijk H, Hoes AW, et al. Duration of hormonal replacement therapy in general practice: a follow-up study. Maturitas 1998;29:125-31.
14. Olensen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J, Bergman U, et al. Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol 1999;47:323-8.
15. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain 1996-2000. BJOG 2002;109:1319-30.
16. Benet MB, Carvajal A, García del Pozo J, Álvarez Requejo A, Vega Alonso T, et al. Tratamiento hormonal sustitutivo en España. Un estudio de utilización. Med Clin (Barc) 2002;119:4-8.
17. Progetto Menopausa Study Group. General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy. Menopause 2001;8:290-5.
18. Calaf J. SERM's: efectos secundarios y posicionamiento clínico. En: Cano A, Calaf J, editores. Moduladores selectivos de los receptores de estrógenos. Barcelona: Doyma, 2000; p. 143-61.
19. Rozenberg S, Lefever A, Kroll M, Vandromme J, Paesmans M, Ham H, et al. Prescription attitudes among gynecologists towards two particular risk factors of osteoporosis: the patient's age and her bone mineral density. Maturitas 1999;32:19-24.